Liquid Biopsies Bleed Into Clinical Use

Technologies that can detect cancer in circulating blood have proliferated over the past few years, but proof of their prowess in the clinic has been lacking. In April, researchers at the Dana-Farber
Cancer Institute published the first prospective study for a cancer liquid biopsy, which showed that an in-house blood test could detect key mutations in the genes EGFR and KRAS in advanced lung cancer with a specificity high enough to drive treatment.